Actualités

Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

Biogen Inc (BIIB) reports a 3% revenue increase, driven by a robust growth portfolio and strategic acquisitions, despite facing market challenges.

Moby summary of Biogen Inc.'s Q2 2026 earnings call

Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.

Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth port

Biogen (BIIB) delivered earnings and revenue surprises of +18.42% and +9.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.

Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for.

BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.

Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.

Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.